Nothing Special   »   [go: up one dir, main page]

PL1926722T3 - Podstawione benzimidazole jako inhibitory kinaz - Google Patents

Podstawione benzimidazole jako inhibitory kinaz

Info

Publication number
PL1926722T3
PL1926722T3 PL06824870T PL06824870T PL1926722T3 PL 1926722 T3 PL1926722 T3 PL 1926722T3 PL 06824870 T PL06824870 T PL 06824870T PL 06824870 T PL06824870 T PL 06824870T PL 1926722 T3 PL1926722 T3 PL 1926722T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
substituted benzimidazoles
benzimidazoles
substituted
kinase
Prior art date
Application number
PL06824870T
Other languages
English (en)
Inventor
Mina E Aikawa
Payman Amiri
Jeffrey H Dove
Barry Haskell Levine
Christopher Mcbride
Teresa E Pick
Daniel J Poon
Savithri Ramurthy
Paul A Renhowe
Cynthia Shafer
Darrin Stuart
Sharadha Subramanian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1926722T3 publication Critical patent/PL1926722T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06824870T 2005-08-30 2006-08-30 Podstawione benzimidazole jako inhibitory kinaz PL1926722T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US71253905P 2005-08-30 2005-08-30
US71310805P 2005-08-30 2005-08-30
US73159105P 2005-10-27 2005-10-27
US77468406P 2006-02-17 2006-02-17
EP06824870A EP1926722B1 (en) 2005-08-30 2006-08-30 Substituted benzimidazoles as kinase inhibitors
PCT/US2006/034088 WO2007030377A1 (en) 2005-08-30 2006-08-30 Substituted benzimidazoles as kinase inhibitors

Publications (1)

Publication Number Publication Date
PL1926722T3 true PL1926722T3 (pl) 2012-02-29

Family

ID=37434025

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06790127T PL1924577T3 (pl) 2005-08-30 2006-08-30 Podstawione benzimidazole i sposoby ich wytwarzania
PL06824870T PL1926722T3 (pl) 2005-08-30 2006-08-30 Podstawione benzimidazole jako inhibitory kinaz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06790127T PL1924577T3 (pl) 2005-08-30 2006-08-30 Podstawione benzimidazole i sposoby ich wytwarzania

Country Status (37)

Country Link
US (6) US7482367B2 (pl)
EP (2) EP1924577B1 (pl)
JP (4) JP5210866B2 (pl)
KR (2) KR20080039965A (pl)
AR (2) AR057109A1 (pl)
AT (2) ATE526325T1 (pl)
AU (2) AU2006284666B2 (pl)
BR (2) BRPI0615314A2 (pl)
CA (2) CA2620472C (pl)
CR (1) CR9716A (pl)
CU (1) CU23784B7 (pl)
CY (2) CY1111871T1 (pl)
DE (1) DE602006021036D1 (pl)
DK (2) DK1924577T3 (pl)
EA (1) EA014230B1 (pl)
EC (2) ECSP088210A (pl)
ES (1) ES2374451T3 (pl)
GE (1) GEP20105004B (pl)
GT (1) GT200600394A (pl)
HK (2) HK1117519A1 (pl)
HN (1) HN2008000317A (pl)
HR (2) HRP20110312T1 (pl)
IL (2) IL189080A (pl)
MA (2) MA29915B1 (pl)
MY (2) MY163886A (pl)
NI (1) NI200800060A (pl)
NO (1) NO20081476L (pl)
NZ (2) NZ565450A (pl)
PE (2) PE20070335A1 (pl)
PL (2) PL1924577T3 (pl)
PT (2) PT1926722E (pl)
RS (1) RS52099B (pl)
SI (2) SI1926722T1 (pl)
SM (1) SMP200800022B (pl)
TN (2) TNSN08089A1 (pl)
TW (2) TW200804345A (pl)
WO (2) WO2007027950A1 (pl)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
EP2046292B1 (en) * 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
CN101541977A (zh) * 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
RU2483064C2 (ru) * 2007-03-02 2013-05-27 Новартис Аг Твердые формы ингибитора raf-киназы
BRPI0811097A2 (pt) * 2007-05-23 2014-12-09 Novartis Ag Inibidores de raf para o tratamento de câncer de tireoide
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
EP2184285B1 (en) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP2011524362A (ja) * 2008-06-13 2011-09-01 ノバルティス アーゲー 神経線維腫症用の置換ベンゾイミダゾール
EP2310050A1 (en) * 2008-07-11 2011-04-20 Novartis AG Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
US8563746B2 (en) * 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010064611A1 (ja) 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2011020936A (ja) * 2009-07-14 2011-02-03 Lotte Co Ltd 口臭除去剤
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
US20130231347A1 (en) * 2010-11-19 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
CN103764144B (zh) 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
RU2641693C2 (ru) * 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
BR112014011223A8 (pt) 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
UA115039C2 (uk) 2011-11-23 2017-09-11 Еррей Біофарма Інк. Фармацевтичні композиції
PL2855448T3 (pl) 2012-05-15 2017-09-29 Cancer Research Technology Ltd 5-[[4-[[morfolino-2-ilo]metyloamino]-5-(trifluorometylo)-2-pirydylo]amino]pirazyno-2-karbonitryl i jego zastosowanie terapeutyczne
JP2015536964A (ja) 2012-11-08 2015-12-24 ノバルティス アーゲー B−raf阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用
HUE055072T2 (hu) 2013-03-21 2021-10-28 Array Biopharma Inc B-Raf gátlót és második gátlószert tartalmazó kombinációs terápia
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CR20160425A (es) 2014-03-14 2017-05-26 Novartis Ag Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
MX2017011597A (es) 2015-03-10 2018-05-11 Aduro Biotech Inc Composiciones y metodos para activar la señalizacion dependiente del "estimulador del gen de interferon".
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
MX2018000024A (es) 2015-06-30 2018-06-27 Sequessome Tech Holdings Limited Formulaciones mezcladas.
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
CN108473584B (zh) 2015-11-03 2022-01-14 詹森生物科技公司 特异性结合pd-1和tim-3的抗体及其用途
CN105481944B (zh) * 2015-12-10 2019-01-08 华南农业大学 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
JP7094942B2 (ja) * 2017-03-15 2022-07-04 住友ファーマ株式会社 ベンズイミダゾール誘導体の製造方法
CR20190519A (es) * 2017-04-18 2020-03-06 Lilly Co Eli Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
KR20200021087A (ko) 2017-06-22 2020-02-27 노파르티스 아게 Cd73에 대한 항체 분자 및 이의 용도
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US20230183204A9 (en) * 2018-11-07 2023-06-15 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3126021A1 (en) 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894037A (en) 1971-05-24 1975-07-08 Ciba Geigy Corp Certain isothiocyanobenzimidazoles
CH634306A5 (de) 1977-04-12 1983-01-31 Ciba Geigy Ag Benzimidazolderivate, verfahren zu ihrer herstellung und anthelmintische mittel enthaltend diese verbindungen als wirkstoffe.
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd 3−ヒドロキシ−ml−236b誘導体の製造法
US4430502A (en) 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
FR2677020B1 (fr) 1991-05-31 1993-08-27 Cird Galderma Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique.
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0604181A1 (en) 1992-12-21 1994-06-29 Eli Lilly And Company Antitumor compositions and method of treatment
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
WO1994026723A2 (en) 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
IL113196A0 (en) 1994-03-31 1995-06-29 Bristol Myers Squibb Co Imidazole derivatives and pharmaceutical compositions containing the same
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
EP0701907A1 (en) 1994-09-13 1996-03-20 Agfa-Gevaert N.V. A dye donor element for use in a thermal dye transfer process
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
ATE261961T1 (de) 1995-11-17 2004-04-15 Biotechnolog Forschung Gmbh Epothilon-derivate, ihre herstellung und verwendung
US6166219A (en) 1995-12-28 2000-12-26 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
CN1098256C (zh) 1996-04-12 2003-01-08 G·D·瑟尔公司 作为cox-2抑制剂前药的取代的苯磺酰胺衍生物
WO1997044058A1 (en) 1996-05-23 1997-11-27 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
FR2751649B1 (fr) 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6127380A (en) 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
US5932600A (en) 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
HUP0003934A3 (en) 1997-07-03 2002-01-28 Pfizer A part of diaryl imidazole derivatives, pharmaceutical composit
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
FR2766822B1 (fr) 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
CN1302296A (zh) 1998-05-22 2001-07-04 史密丝克莱恩比彻姆公司 新的2-烷基取代咪唑化合物
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
FR2780973B1 (fr) 1998-07-09 2001-10-05 Hoechst Marion Roussel Inc Procede de preparation du 4-(3-pyridinyl)-1h-imidazole, et les intermediaires mis en oeuvre
DE19834751A1 (de) 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2369728A1 (en) 1999-04-12 2000-10-19 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists
ATE323482T1 (de) 1999-07-02 2006-05-15 Stuart A Lipton Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
EP1263753B1 (en) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
EP1268432A1 (en) 2000-03-24 2003-01-02 Millenium Pharmaceuticals, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
EP1272483A2 (en) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
JP2001322903A (ja) 2000-05-15 2001-11-20 Kumiai Chem Ind Co Ltd 農園芸用殺菌剤組成物
JP2004505061A (ja) * 2000-07-27 2004-02-19 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とカルシウムチャンネル遮断薬の併用療法
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
JP4734705B2 (ja) 2000-10-31 2011-07-27 三菱化学株式会社 リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
HUP0303494A3 (en) 2000-12-15 2009-08-28 Vertex Pharma Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP2004531479A (ja) * 2001-02-08 2004-10-14 カロ バイオ アクチェブラーグ 甲状腺受容体リガンドとしてのフェノキシ置換されたベンゾ縮合ヘテロアリール誘導体
WO2002076454A1 (en) * 2001-03-26 2002-10-03 Unisearch Limited Method for treatment of cancer and compositions for use therein
EP1432690A2 (en) * 2001-04-16 2004-06-30 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
AU2002332099B2 (en) 2001-10-09 2007-12-13 Amgen Inc. Imidazole derivates as antiinflammatory agents
US7039413B2 (en) * 2001-10-24 2006-05-02 Ntt Docomo, Inc. Mobile station transfer control system, cell transfer control method, mobile station, cell transfer control method at mobile station, cell transfer control program, control apparatus, and allocating method of communication resources
TW200300140A (en) 2001-11-14 2003-05-16 Novartis Ag Organic compounds
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
JP4136395B2 (ja) 2002-02-22 2008-08-20 クミアイ化学工業株式会社 農園芸用殺菌剤組成物
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
KR20110015702A (ko) * 2002-03-29 2011-02-16 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치환된 벤자졸 및 raf 키나아제 저해제로서의 그들의 이용
US7524841B2 (en) 2002-04-25 2009-04-28 Teijin Limited 4,4-disubstituted piperidine derivatives having CCR3 antagonism
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
TWI341314B (en) 2002-08-09 2011-05-01 Astrazeneca Ab New compounds
CA2498047C (en) * 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
AU2003271548A1 (en) 2002-10-13 2004-05-04 Neurosearch A/S Use of skca channel blocking drugs for combating parkinson's disease
US7122665B2 (en) 2002-10-15 2006-10-17 Synta Pharmaceuticals Corp. Heterocyclic compounds
US20050054705A1 (en) * 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP2258365B1 (en) * 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
RU2374241C2 (ru) 2003-05-20 2009-11-27 Новартис Аг N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы
EP1626725A4 (en) 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
AU2004255342C1 (en) 2003-07-08 2009-05-14 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US20060205740A1 (en) 2003-08-14 2006-09-14 Reno Michael J Chemical compounds
SI2392565T1 (sl) 2003-09-26 2014-05-30 Exelixis, Inc. c-Met modulatorji in postopki uporabe
KR20060118472A (ko) 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 raf 키나아제의 저해제로서 그것의 사용
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
EP2046292B1 (en) * 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers

Also Published As

Publication number Publication date
US7767820B2 (en) 2010-08-03
ECSP088218A (es) 2008-03-26
US20100234394A1 (en) 2010-09-16
AU2006287688B2 (en) 2010-08-19
HRP20110939T1 (hr) 2012-01-31
AR055622A1 (es) 2007-08-29
AR057109A1 (es) 2007-11-14
ATE526325T1 (de) 2011-10-15
NO20081476L (no) 2008-03-26
TNSN08089A1 (en) 2009-07-14
KR20080039965A (ko) 2008-05-07
PT1924577E (pt) 2011-07-04
US20080287682A1 (en) 2008-11-20
AU2006284666A1 (en) 2007-03-08
ATE503751T1 (de) 2011-04-15
US20090170904A1 (en) 2009-07-02
PE20070335A1 (es) 2007-04-21
PT1926722E (pt) 2012-01-11
SI1926722T1 (sl) 2012-01-31
AU2006284666B2 (en) 2011-04-28
US20070161680A1 (en) 2007-07-12
GT200600394A (es) 2008-03-17
US20100256375A1 (en) 2010-10-07
JP5210867B2 (ja) 2013-06-12
US8592459B2 (en) 2013-11-26
JP2013060457A (ja) 2013-04-04
MA29915B1 (fr) 2008-11-03
DE602006021036D1 (de) 2011-05-12
TNSN08088A1 (en) 2009-07-14
GEP20105004B (en) 2010-06-10
NZ565451A (en) 2011-05-27
CY1112157T1 (el) 2015-12-09
SI1924577T1 (sl) 2011-07-29
MY148694A (en) 2013-05-31
TWI387592B (zh) 2013-03-01
WO2007030377A1 (en) 2007-03-15
SMAP200800022A (it) 2008-04-02
HK1117523A1 (en) 2009-01-16
MA29772B1 (fr) 2008-09-01
US20070049622A1 (en) 2007-03-01
EP1926722B1 (en) 2011-09-28
JP2009507794A (ja) 2009-02-26
SMP200800022B (it) 2008-04-02
US7732465B2 (en) 2010-06-08
HRP20110312T1 (hr) 2011-08-31
KR20080039964A (ko) 2008-05-07
RS52099B (en) 2012-06-30
JP2013060458A (ja) 2013-04-04
IL189194A0 (en) 2008-06-05
CA2620472C (en) 2013-12-24
TW200804345A (en) 2008-01-16
NZ565450A (en) 2011-04-29
WO2007027950A1 (en) 2007-03-08
EP1924577A1 (en) 2008-05-28
BRPI0615309B1 (pt) 2021-07-27
EP1924577B1 (en) 2011-03-30
HN2008000317A (es) 2011-02-16
JP5210866B2 (ja) 2013-06-12
PL1924577T3 (pl) 2011-09-30
CY1111871T1 (el) 2015-11-04
TW200804346A (en) 2008-01-16
US7482367B2 (en) 2009-01-27
CU20080027A7 (es) 2010-12-08
EA014230B1 (ru) 2010-10-29
HK1117519A1 (en) 2009-01-16
IL189194A (en) 2013-09-30
DK1926722T3 (da) 2011-12-19
DK1924577T3 (da) 2011-05-16
IL189080A (en) 2013-05-30
MY163886A (en) 2017-11-15
PE20070427A1 (es) 2007-04-21
CA2619966A1 (en) 2007-03-08
BRPI0615314A2 (pt) 2011-05-17
CU23784B7 (es) 2012-02-15
JP2009507026A (ja) 2009-02-19
AU2006287688A1 (en) 2007-03-15
EA200800441A1 (ru) 2008-08-29
CR9716A (es) 2008-04-16
CA2620472A1 (en) 2007-03-15
BRPI0615309A2 (pt) 2011-05-17
EP1926722A1 (en) 2008-06-04
ES2374451T3 (es) 2012-02-16
NI200800060A (es) 2009-03-03
IL189080A0 (en) 2008-08-07
ECSP088210A (es) 2008-03-26

Similar Documents

Publication Publication Date Title
IL189194A0 (en) Substituted benzimidazoles as kinase inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL190078A0 (en) Kinase inhibitors
EP1951715A4 (en) AMINOPYRIMIDINES USEFUL AS INHIBITORS OF KINASES
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
PT2200436E (pt) Pirimidinilaminas substituídas como inibidoras da proteína quinase
ZA200901073B (en) Kinase inhibitor
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
SI1943243T1 (sl) Inhibotorji kinaz
EP1968581A4 (en) TETRACYCLIC KINASE INHIBITORS
HK1112918A1 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
IL197981A0 (en) Kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
ZA200804768B (en) Aminopyrimidines useful as kinase inhibitors
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors